drugset / Trial / NCT01318915
Research Study of ATG and Rituximab in Renal Transplantation
Phase 0
Terminated
10 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance Network (ITN) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is see if a combination of two drugs, (ATG and rituximab), given at the time of the transplant surgery, will help reduce or eliminate the need for long term immunosuppressive medication.
Timeline
- Start
- 2011-07-25
- Primary completion
- 2016-06-17
- Completion
- 2017-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATG | Unknown | 1.5 mg/kg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Sirolimus | Small molecule | 2 mg | Oral |
| Subject | Tacrolimus | Small molecule | — | Oral |
| Background | MMF | Unknown | 1 g | — |